As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: March 26, 2012
by News Wise
Alzheimer’s disease (AD) steals memory and ruins lives. Despite near-daily reports of promising new therapies, AD remains unchecked. Now a new study reveals the mechanism by which AD may cause memory loss, suggesting new therapies.
AD brains have two types of lesions: beta-amyloid plaques outside neurons, and neurofibrillary tangles within them. The known AD genes implicate plaques, but AD symptoms correlate more closely with tangles, comprised of “tau” protein, normally adhered to microtubules. Excess beta-amyloid plaques induce tangles, disrupt microtubules, and cause memory loss, even with normal synaptic function. But how?
In the March 23 issue of the journal PLoS One, scientists from Harvard, Boston University, The University of Alberta, The University of Arizona and The Chopra Foundation ascribe AD memory loss to disruption of microtubules by zinc imbalance.
Previously, Harvard’s Dr. Rudolph Tanzi, senior author on the present study, showed with colleagues that plaques outside neurons sequester zinc, lowering levels inside neurons. Zinc stabilizes many protein complexes, including microtubules (MTs), polymers of tubulin. MTs regulate synapses, and play recently-revealed key roles in memory encoding in neurons.
In the present study, Craddock et al identify specific zinc-tubulin binding sites promoting side-to-side tubulin interactions, critical to MT polymer structure, 2) show via kinetic analysis how extra-neuronal zinc sequestration reduces intra-neuronal zinc available to tubulin, destabilizing MTs and leading to tangles. And, 3) they present metallomic imaging mass spectrometry (MIMS) of AD model mice revealing abnormal zinc distribution in critical brain regions.
This view of AD suggests therapies based on stabilizing MTs by normalizing intra-neuronal zinc levels by zinc ionophore drugs such as PBT2 (Prana Biotechnology), and 2) promoting MT self-assembly and stability by other drugs, as well as transcranial therapies, e.g. ultrasound at MT resonant frequencies in megahertz.
Tanzi, senior author and Harvard’s leading Alzheimer’s expert said: “It looks like beta-amyloid plaques themselves aren’t destructive directly, but lead to lower zinc levels within neurons. This in turn disrupts microtubules and tau, causing tangles and memory loss. Protecting microtubules and their association with tau may be the best treatment approach in Alzheimers disease.”
Source: http://www.newswise.com/articles/view/587318/?sc=rsmn
Diagnosis of dementia is made via cognitive function tests such as the Mini-Mental State Examination (MMSE) and medical imaging systems at hospitals, a fairly large system for the purpose. As the population ages, an increasing number of...
In the past eight years, the Canadian Institutes of Health Research (2010), the European Commission (2014), and more recently the National Institutes of Health (2015), have announced policies requiring basic and clinical researchers to integrate sex as...
Two strains of human herpesvirus—human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7)—are found in the brains of individuals with Alzheimer’s disease at levels up to twice as high as in those without Alzheimer’s, according to...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.
